Navigation Links
Novozymes Launches Enzyme to Reduce Acrylamide in Food
Date:8/31/2007

DITTINGEN, Switzerland, August 31 /PRNewswire/ -- Researchers from Novozymes, the world leader in bio-innovations and bio-solutions have found a solution to reduce the level of acrylamide in food products such as cookies, crackers and snacks.

Novozymes launches Acrylaway to reduce acrylamide which is formed when starchy foods are baked, fried or toasted at high temperatures. Acrylamide is under suspicion of causing cancer.

Health concerns

In 2002, a study by the Swedish National Food Authorities discovered considerable levels of acrylamide in food products such as French fries, biscuits, snacks and crackers. The study raised awareness of acrylamide worldwide. A new enzyme called Acrylaway addresses this problem.

Acrylaway can be applied to a wide range of products opening up for an overall reduction of average daily intake of acrylamide for consumers worldwide.

"It is a fundamental need for consumers and society that our food is safe and healthy. With the enzyme solution from Novozymes, food manufacturers can now offer end-consumers food products with reduced worries regarding acrylamide" says Peder Holk Nielsen, Executive Vice President, Sales & Marketing at Novozymes.

Acrylamide is reduced up to 90%

Independent tests show that Acrylaway effectively reduces acrylamide levels by 50% to 90% in a broad range of foods such as biscuits, crackers, crisp bread and snacks.

"Many food manufacturers globally have already tested Acrylaway and have shown interest in the product and its ability to substantially reduce acrylamide without changing the taste and appearance of their food product," Peder Holk Nielsen says.

In November 2006, Novozymes received a consent letter from the US Food & Drug Administration regarding the generally recognized as safe (GRAS) status of the asparaginase enzyme. In June 2007 Acrylaway was approved by the Danish authorities and thereby is the first asparaginase that has been safety evalua
'/>"/>

SOURCE Novozymes Switzerland AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Merge launches diagnostic mammography workstation in Europe
2. Einstein Wireless launches cellular alert system
3. Logistics Health launches compliance management tool
4. UW-Madison launches new high-speed research network
5. UWM launches research foundation
6. TeraMedica launches information manager
7. GE Healthcare launches hybrid electronic record
8. Cedara launches new version of DICOM toolkit
9. Merge launches Spanish version of imaging tool
10. Doyle launches 2025 alternative energy plan
11. Jellyfish launches comparative shopping website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Steep Hill, the industry leader in ... intends to open a full service medical cannabis quality ... , bringing advanced scientific tools and methodology to the ... Hill is currently the only laboratory licensed by the ... contaminant testing in order to meet the recently adopted ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... , Feb. 26, 2015  23andMe, the leading ... Kate Black as Privacy Officer and Corporate Counsel. ... state privacy laws as well as health care regulations. ... she will be responsible for reviewing, updating and enhancing ... the U.S. and abroad. She joined the company January ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... safety and efficacy of Albuferon administered every four weeks in ... hepatitis C - , , ROCKVILLE, Md., June 19 ... today announced that Novartis has completed enrollment and initial dosing ... and efficacy of Albuferon(R) (albinterferon alfa-2b) administered monthly in combination ...
... Has Tentative FDA Approval and Expects Final Approval Shortly -- ... Inc. (NYSE: HSP ), the world leader in ... for the District of New Jersey has granted summary judgment ... chemotherapy medication Eloxatin(R), and that Hospira has tentative approval from ...
... WalkMS Participants - , , NEW YORK, June ... family, and other people living with multiple sclerosis, Saatchi & ... component of the "I Walk Because" program. The site ... social media applications. , , The site, ...
Cached Biology Technology:Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 2Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 3Human Genome Sciences Announces Completion of Enrollment in Phase 2b Monthly-Dosing Trial of Albuferon(R) 4Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3I Walk Because Program Gives Consumers a Voice 2I Walk Because Program Gives Consumers a Voice 3
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... Online CEO Conference on January 29 th at ... , CEO of NXT-ID will present and host a ... smart wallet and its full suite of biometric technologies. ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... IOF and ESCEO will be staging the ... largest bone meeting in Europe, to be held ... the pre-registration deadline of March 7, 2011 fast ... registration to the 1st IOF-ESCEO Pre-Clinical Symposium (from ...
... Scientists have published results that will forever change the ... replication and the prevention of DNA damage. ... to many problems including cancers. Researchers, funded by the ... Wellcome Trust and working at The University of Nottingham, ...
... Chase, MDA recent study accepted for publication in ... for the first time that maternal fructose intake during ... endocrinology. Fructose is a simple sugar found naturally ... dietary fructose, particularly due to calorically sweetened beverages, are ...
Cached Biology News:8 special sessions at European Congress on Osteoporosis and Osteoarthritis in Valencia 2Collisions of protein machines cause DNA replication derailment 2Maternal fructose intake impacts female and male fetuses differently 2
... Nuclease is a genetically engineered endonuclease. This ... and RNA while having no proteolytic activity. ... of conditions and possesses an exceptionally high ... acids from recombinant proteins, its use enables ...
...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
...
Biology Products: